PT  - JOURNAL ARTICLE
AU  - SUNGYUB LEW
AU  - RONALD S. CHAMBERLAIN
TI  - Risk of Metabolic Complications in Patients with Solid Tumors Treated with mTOR inhibitors: Meta-analysis
DP  - 2016 Apr 01
TA  - Anticancer Research
PG  - 1711--1718
VI  - 36
IP  - 4
4099  - http://ar.iiarjournals.org/content/36/4/1711.short
4100  - http://ar.iiarjournals.org/content/36/4/1711.full
SO  - Anticancer Res2016 Apr 01; 36
AB  - Background/Aim: Numerous trials have described a wide variation of metabolic complications associated with the mammalian target of rapamycin inhibitors (mTORi). This analysis aimed to report and critically analyze the risks of mTORi-associated metabolic complications. Materials and Methods: A comprehensive search of all published phase II or III randomized controlled trials were investigated. Outcomes included were adverse effect profiles of hyperglycemia (HGC), hypertriglyceridemia (HTG), and hypercholesterolemia (HCE). Results: Sixteen phase II/III clinical trials were identified. The overall incidence of all-grade (AG) and high-grade (HG) metabolic complications associated with mTORi were 39.7% and 4.1% respectively. mTORi use was associated with an increased risk of AG (2.97 [2.25-3.92]) and HG HGC (4.08 [2.71-6.14]), AG (2.22 [1.70-2.89]) and HG HTG (1.88 [1.10-3.20]), and AG (2.48 [1.83-3.36]) and HG HCE (4.26 [2.30-7.90]). Conclusion: mTORi are associated with a significantly increased risk of AG and HG HGC, HTG, and HCE. Clinicians should be aware of these risks, perform regular monitoring, and consider alternative anti-neoplastic treatments or adjunctive pharmacological intervention if necessary.